Profile data is unavailable for this security.
About the company
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
- Revenue in JPY (TTM)3.60bn
- Net income in JPY-883.62m
- Incorporated2001
- Employees42.00
- LocationKidswell Bio Corp3F, Kanayama Bldg., 1-2-12, ShinkawaCHUO-KU 104-0033JapanJPN
- Phone+81 362229547
- Fax+81 362229548
- Websitehttps://www.kidswellbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PhoenixBio Co Ltd | 1.62bn | -126.00m | 1.47bn | 70.00 | -- | 0.8701 | -- | 0.9056 | -31.31 | -31.31 | 408.76 | 416.03 | 0.5679 | 1.05 | 5.81 | 23,168,070.00 | -4.41 | -4.04 | -6.32 | -5.28 | 72.27 | 65.88 | -7.77 | -6.97 | 3.65 | -1.07 | 0.207 | -- | -19.24 | 6.91 | -94.65 | -- | -9.96 | -- |
| Ribomic Inc | 2.11m | -949.28m | 3.30bn | 24.00 | -- | 1.00 | -- | 1,564.81 | -25.76 | -25.76 | 0.057 | 80.86 | 0.0006 | -- | 0.0677 | 87,791.66 | -25.76 | -30.52 | -26.68 | -31.71 | -- | -- | -45,053.58 | -1,777.84 | 30.87 | -- | 0.00 | -- | -100.00 | -- | 38.04 | -- | 4.42 | -- |
| Human Metabolome Technologies Inc | 1.38bn | 246.02m | 3.58bn | 58.00 | 14.52 | 1.97 | 10.24 | 2.58 | 41.59 | 41.59 | 234.08 | 306.43 | 0.6291 | 8.87 | 7.76 | 23,872,380.00 | 11.18 | 8.49 | 14.00 | 10.80 | 65.13 | 69.25 | 17.77 | 13.21 | 3.73 | 33.22 | 0.1088 | 18.31 | 3.57 | -- | -14.88 | -- | -- | -- |
| Cyfuse Biomedical KK | 57.69m | -718.81m | 3.68bn | 21.00 | -- | 1.35 | -- | 63.72 | -89.81 | -89.81 | 7.24 | 335.21 | 0.0147 | 0.5261 | 40.19 | 2,747,238.00 | -18.36 | -- | -21.62 | -- | 55.40 | -- | -1,245.95 | -- | 5.52 | -91.45 | 0.2268 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
| D.Western Therapeutics Institute Inc | 464.18m | -1.09bn | 4.25bn | 21.00 | -- | 4.34 | -- | 9.16 | -33.74 | -33.74 | 14.43 | 25.80 | 0.19 | 0.3314 | 4.10 | 22,103,620.00 | -44.77 | -13.06 | -47.81 | -14.36 | 91.27 | 94.29 | -235.62 | -72.51 | 18.24 | -- | 0.5644 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| BrightPath Biotherapeutics Co Ltd | 84.00k | -1.15bn | 4.26bn | 24.00 | -- | 3.39 | -- | 50,768.63 | -16.73 | -16.73 | 0.0012 | 14.73 | 0.00006 | -- | 2.80 | 3,500.00 | -80.63 | -51.56 | -97.29 | -54.32 | 75.00 | 68.63 | -1,372,495.00 | -22,321.82 | -- | -- | 0.2085 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
| FunPep Co Ltd | 530.00k | -727.29m | 4.41bn | 15.00 | -- | 1.65 | -- | 8,316.22 | -29.40 | -29.40 | 0.0215 | 82.55 | 0.0002 | -- | -- | 35,333.33 | -26.27 | -27.10 | -29.12 | -28.75 | -- | -- | -137,223.40 | -815.82 | 5.06 | -1,004.01 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| Kidswell Bio Corp | 3.60bn | -883.62m | 4.63bn | 42.00 | -- | 5.41 | -- | 1.29 | -22.78 | -22.78 | 92.26 | 21.08 | 0.9182 | 2.73 | 6.63 | 85,697,070.00 | -22.54 | -57.41 | -35.96 | -81.13 | 36.17 | 55.20 | -24.55 | -123.52 | 1.64 | -17.95 | 0.7132 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| DNA Chip Research Inc | 766.32m | -118.13m | 4.73bn | 37.00 | -- | 6.74 | -- | 6.17 | -18.29 | -18.29 | 116.80 | 103.64 | 0.9159 | 8.50 | 7.86 | 20,711,350.00 | -14.12 | -23.49 | -17.74 | -26.70 | 38.52 | 14.28 | -15.41 | -54.10 | 2.78 | -641.51 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| Carna Biosciences, Inc. | 1.40bn | -1.51bn | 5.52bn | 67.00 | -- | 1.96 | -- | 3.94 | -85.98 | -85.98 | 80.34 | 147.09 | 0.391 | 1.19 | 13.59 | 20,922,580.00 | -42.15 | -14.45 | -45.45 | -16.95 | 87.53 | 90.59 | -107.80 | -35.42 | 11.11 | -- | 0.0215 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Veritas In Silico Inc | 246.24m | -148.31m | 5.85bn | 15.00 | -- | 2.54 | -- | 23.76 | -23.92 | -23.92 | 38.93 | 354.61 | 0.1227 | -- | -- | 16,415,930.00 | -7.39 | -- | -7.65 | -- | -- | -- | -60.23 | -- | 67.03 | -- | -- | -- | 101.54 | -- | 123.38 | -- | -- | -- |
| Kringle Pharma Inc | 80.04m | -756.45m | 6.00bn | 13.00 | -- | 2.85 | -- | 74.97 | -118.21 | -118.21 | 12.71 | 309.55 | 0.0298 | -- | 1.15 | -- | -28.14 | -19.17 | -30.03 | -20.40 | -- | -- | -945.12 | -181.86 | 19.20 | -- | -- | -- | 15.58 | -- | 11.44 | -- | -- | -- |
| Chiome Bioscience Inc | 581.07m | -1.22bn | 6.24bn | 51.00 | -- | 5.04 | -- | 10.75 | -22.07 | -22.07 | 10.53 | 19.85 | 0.3371 | 5.16 | 8.01 | 11,393,550.00 | -70.61 | -50.50 | -95.97 | -57.38 | 53.55 | 57.53 | -209.45 | -224.74 | 3.57 | -894.37 | 0.1995 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Kidswell Bio Corp's reporting currency: Japanese Yen JPY
0.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 20 Aug 2024 | 169.97k | 0.42% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
